Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st January, 2022 and the same will remain closed till 48 hours after the declaration of Financial Results for the quarter and nine months ending 31st December, 2021, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
31-12-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Board Meeting Outcome for Outcome Of The Board Meeting

 With reference to the above subject, In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. December 14, 2021 at 9:30 a.m., has taken on record the following: Suven Pharma Inc., USA, WOS of Suven Pharmaceuticals Limited (SPL) has divested its entire stake in Rising Pharma Holdings, Inc., USA on 13th December, 2021 to Raisin Aggregator, L.P. USA one of the investment arm of H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with over $45 billion of equity capital under management. As part of the structured deal Suven Pharma Inc., USA received cash and 7% stake in Raisin Aggregator, L.P. USA, the new company. The details are as under:
14-12-2021

Suven Pharma Standalone September 2021 Net Sales at Rs 300.99 crore, up 26.79% Y-o-Y

 NULL
09-11-2021

Earnings Call for Q2FY22 of Suven Pharmaceuticals

 Conference Call with Suven Pharmaceuticals Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
08-11-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and half-year ended September 30, 2021. The advertisements as appeared today i.e. November 8, 2021 in Andhra Prabha (Telugu) and Business Standard. The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements
08-11-2021
Bigul

Q2FY22 Quarterly Result Announced for Suven Pharmaceuticals Ltd.

 Highlights: PAT (Standalone) include INR 332.94 Mn, Dividend from Suven Pharma, Inc., USA. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO). The consolidated financials include the results of the wholly owned subsidiary Suven Pharma, Inc., and associate Rising Pharma Holdings, Inc., USA. The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA. Apart from the above, the shortage or non-availability of vessels leading to delay in shipments, increase in the transportation and distribution costs and timely non availability of materials with increase in materials cost are impacting our operations and profitability. Result PDF
08-11-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find enclosed Investor Presentation
06-11-2021

Suven Pharma Q2 results: Net profit jumps 31% at Rs 97 crore

 Revenue from operations rose to Rs 301 crore for the quarter under review, as against Rs 237 crore in the year-ago period, Suven Pharmaceuticals said in a regulatory filing.
06-11-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half-Year Ended 30Th September, 2021

 With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. November 6, 2021, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2021. Suven Pharmaceuticals Ltd . We are enclosing herewith the following documents: 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2021 2) Limited Review Reports on the financial results as mentioned above and 3) A copy of the News Release of our company We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M.
06-11-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Monday, November 8, 2021 at 12:00 Noon IST to discuss the Un-Audited Financial Results for the Q2 & H1FY22, to be declared on November 06, 2021.
30-10-2021
Next Page
Close

Let's Open Free Demat Account